CAMBRIDGE, MA – Moderna , Inc. (NASDAQ:MRNA) has initiated a Phase 3 clinical trial for its investigational norovirusvaccine, marking a significant step toward addressing the widespread public ...
Some results have been hidden because they may be inaccessible to you